

University of Dundee

## Symptom Onset in Aortic Stenosis - Relation to Sex Differences in Left Ventricular Remodelling

Singh, Anvesha ; Chan, Daniel C. S.; Greenwood, John P.; Dawson, Dana K.; Sonecki, Piotr; Hogrefe, Kai

*Published in:*  
JACC. Cardiovascular Imaging

*DOI:*  
[10.1016/j.jcmg.2017.09.019](https://doi.org/10.1016/j.jcmg.2017.09.019)

*Publication date:*  
2019

*Licence:*  
CC BY-NC-ND

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Singh, A., Chan, D. C. S., Greenwood, J. P., Dawson, D. K., Sonecki, P., Hogrefe, K., Kelly, D. J., Dhakshinamurthy, V., Lang, C., Khoo, J. P., Sprigings, D., Steeds, R. P., Zhang, R., Ford, I., Jerosch-Herold, M., Yang, J., Li, Z., Ng, L. L., & McCann, G. P. (2019). Symptom Onset in Aortic Stenosis - Relation to Sex Differences in Left Ventricular Remodelling. *JACC. Cardiovascular Imaging*, 12(1), 96-105. <https://doi.org/10.1016/j.jcmg.2017.09.019>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## **Symptom Onset in Aortic Stenosis – Relation to Sex Differences in Left Ventricular Remodelling**

Anvesha Singh<sup>1</sup> (MBChB, PhD); Daniel C.S. Chan<sup>1</sup> (BMedSci, BMBS); John P. Greenwood<sup>2</sup> (MBChB, PhD); Dana K. Dawson<sup>3</sup> (DM, PhD); Piotr Sonecki<sup>4</sup> (MD); Kai Hogrefe<sup>5</sup> (MD), Damian J. Kelly<sup>6</sup> (MBChB, MD); Vijay Dhakshinamurthy<sup>7</sup> (MBBS); Chim C. Lang<sup>8</sup> (MBChB, MD); Jeffery P. Khoo<sup>9</sup> (MBChB, PhD); David Sprigings<sup>10</sup> (MBChB); Richard P. Steeds<sup>11</sup> (MBBS, MD); Ruiqi Zhang<sup>12</sup> (PhD); Ian Ford<sup>12</sup> (PhD); Michael Jerosch-Herold<sup>13</sup> (PhD); Jing Yang<sup>14</sup> (PhD); Zhuyin Li<sup>14</sup> (PhD); Leong L. Ng<sup>1</sup> (MB Bchir, MD); Gerry P. McCann<sup>1</sup> (MBChB, MD)

1. Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Groby road, Leicester, LE3 9QP, UK.
2. Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds University, Leeds, LS2 9JT, UK
3. Cardiovascular Medicine Research Unit, School of Medicine and Dentistry, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK
4. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK
5. Cardiology Department, Kettering General Hospital Foundation Trust, Rothwell Rd, Kettering NN16 8UZ, UK
6. Cardiology Department, Royal Derby Hospital, Uttoxeter Rd, Derby DE22 3NE, UK
7. Cardiology Department, University Hospital, Clifford Bridge Rd, Coventry CV2 2DX, UK
8. Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
9. Cardiology Department, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK
10. Northampton General Hospital, Cliftonville, Northampton NN1 5BD, UK
11. Institute for Cardiovascular Sciences, University of Birmingham, Department of Cardiology, Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2TH, UK
12. Roberston Centre for Biostatistics, University of Glasgow, Level 11, Boyd Orr Building University Avenue, Glasgow G12 8QQ, UK
13. Brigham and Woman's Hospital and Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA
14. Bristol-Myers Squibb Company, Princeton, NJ, USA

**Brief title:** Sex differences in AS

**Word count:** 3917

**Address for correspondence:**

Dr Anvesha Singh  
Glenfield Hospital, Groby Road  
Leicester LE3 9QP, UK  
Telephone: 0116 2583365  
Fax: 0116 2583422  
Email: as707@le.ac.uk

**Funding:** This study was funded by the National Institute for Health Research (NIHR-PDF 2011-04-51 GPM). The views expressed are those of the authors and not of the NHS, NIHR or the Department of Health. AS was funded by the NIHR Leicester Cardiovascular Biomedical Research Unit. NIHR Comprehensive Local Research Networks and the Leeds and Leicester NIHR Clinical Research Facilities provided further support. D.C.S.C is funded by the British Heart Foundation(FS/15/10/31223). The Luminex® assays were funded and performed by Bristol-Myers-Squibb, Princeton, NJ, USA.

**Relationship with Industry:** J.Y and L.Z are employees of the Bristol-Myers-Squibb company.

**Acknowledgements:** We acknowledge all research staff at each site for their contribution to recruitment and the University of Leicester Clinical Trials Unit for providing trial management support. We also acknowledge the following: Professor Colin Berry (PI) at the University of Glasgow and the following contributors to the experimental design and data analysis of the Luminex assay at the Bristol-Myers Squibb Company: Mary Ellen Cvijic, Lei Zhao, Melissa Yarde, Ni Yan, Paul Kessler, Tom Bradstreet, Jie Pan, Huaping Tang and Resham Panemangalore.

## **Abstract**

**Objectives:** To establish sex differences in remodelling and outcome in aortic stenosis (AS) and their associations with biomarkers of myocardial fibrosis.

**Background:** The remodelling response and timing of symptoms is highly variable in AS, and gender plays an important role.

**Methods:** 174 patients (133 male, mean age  $66.2 \pm 13.3$  years) with asymptomatic moderate to severe AS underwent comprehensive stress cardiac magnetic resonance (CMR) imaging, trans-thoracic echocardiography (TTE) and biomarker analysis (MMP-2, 3, 7, 8 and 9, TIMP-1, 4, syndecan-1 and 4 and NT-proBNP), and were followed up at 6-monthly intervals. A primary endpoint was a composite of typical AS symptoms necessitating referral for AVR, cardiovascular death or major adverse cardiovascular events.

**Results:** For a similar severity of AS, male patients demonstrated higher indexed LV volumes and mass, more concentric remodelling (higher LV mass/volume), a trend to more late gadolinium enhancement (LGE) (present in 51.1% male *vs.* 34.1% female,  $p=0.057$ ) and higher extra-cellular volume index than female patients (13.27 [11.5, 17.0] *vs.* 11.53 [10.5, 13.5] ml/m<sup>2</sup>,  $p=0.017$ ), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, whilst females had higher septal E/e'. Male sex was independently associated with indexed LV mass ( $\beta=13.32$  (9.59-17.05),  $p<0.001$ ). During median follow-up of 374 (IQR 351-498) days, a primary outcome, driven by spontaneous symptom onset, occurred in 21.8% of male and 43.9% of female patients (RR 0.50 (CI 0.31, 0.80),  $p=0.004$ ). Measures of AS severity were associated with the primary outcome in both sexes, whereas NT-proBNP, MMP3 and mass/volume were only associated in males.

**Conclusions:** In AS, females tolerate pressure overload with less concentric remodelling and myocardial fibrosis but are more likely to develop symptoms. This may be related to higher wall stress and filling pressures in females.

**Keywords:** aortic stenosis, sex, remodelling, biomarkers

## **Abbreviations**

AS: aortic stenosis

AVA(I): aortic valve area (index)

AVR: aortic valve replacement

CMR: cardiovascular magnetic resonance

ECV: extracellular volume

MPG: mean pressure gradient

PWV: pulse wave velocity

LGE: late gadolinium enhancement

LV: left ventricle

LVMI: left ventricular mass index

TTE: trans-thoracic echocardiogram

VAI: valvulo-arterial impedance

## **Introduction**

Aortic stenosis (AS) is the commonest valve lesion requiring surgery in the developed world with increasing prevalence with aging populations (1). Symptomatic severe AS is a malignant condition for which International guidelines recommend aortic valve replacement (AVR). The exact mechanisms leading to symptoms are uncertain and patients may remain asymptomatic for many years. Considerable attention has focused on the role of left ventricular (LV) hypertrophy and other changes within the myocardium or “LV remodelling”. This is initially thought to be adaptive, with increased wall thickness leading to normalisation of the wall stress and preservation of cardiac output (2). However, this eventually becomes maladaptive, leading to reduced myocardial perfusion (3,4), interstitial and replacement fibrosis (5,6) and impaired diastolic function (7) and systolic heart failure (8).

The remodelling response and the timing of symptom onset is highly variable. Various observational studies, mainly utilising trans-thoracic echocardiography (TTE) and cardiac catheterisation, have established differences in LV geometry and function between male and female patients with a similar degree of AS, with females demonstrating smaller, more concentrically thickened hearts, with ‘supernormal’ systolic function (9-11). Recent cardiac magnetic resonance (CMR) imaging studies have shown lower LV mass/volume in females (12,13).

Genome-wide association studies have also identified sex-dependent differences, with a greater profibrotic and inflammatory response to pressure overload in men, but suppressed extracellular matrix remodelling and inflammatory gene pathways in female ventricles (14). Matrix metalloproteinases (MMP’s) and their tissue inhibitors (TIMP’s) have been implicated in pathological remodelling(15), progression to diastolic dysfunction(16)and heart failure in AS

(17). Additionally, Syndecan-1 and 4 are increasingly recognized to mediate pro-fibrotic signalling in cardiac fibroblasts (18). As sex differences in these markers have not previously been reported in AS, they were selected to reflect the likely differences in LV remodelling and myocardial fibrosis between sexes.

The aims of this study were to assess whether: differential LV remodelling in female and male patients with AS is associated with: 1. altered cardiac function and circulating biomarkers associated with myocardial fibrosis and 2. clinical outcomes in initially asymptomatic patients.

## **Methods**

### *Subjects*

Asymptomatic patients with moderate to severe AS were recruited as part of the ‘PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with AS’ (PRIMID-AS) study(19,20). The national research ethics service approved the study and written informed consent was obtained from all participants.

### *Investigations*

#### TTE

A comprehensive TTE was performed by an accredited sonographer according to International guidelines (21). All image analysis was conducted at the core lab by a single physiologist, using an Xcelera (Phillips, Best, The Netherlands) workstation, to assess AS severity, diastolic function, strain (using Speckle Tracking) and Valvulo-arterial impedance (VAI)(22). Blood pressure was measured on the same day at rest prior to performing the TTE.

#### CMR

Patients underwent comprehensive multi-parametric 3T CMR (including a stress and rest first-pass perfusion imaging, pre- and post-contrast T1 mapping and late gadolinium

enhancement (LGE) imaging after a total of 0.15 mmol/kg of gadolinium-based contrast agent) as previously described, at five sites within the UK(19). All image analysis was undertaken at the core lab by a single observer (AS), blinded to the patient data. Volumetric, T1 and LGE analysis was performed using *cvi42* version-5 (Circle Cardiovascular Imaging, Calgary, Canada). Papillary muscles were excluded from the myocardial mass analysis. The presence or absence of late-gadolinium enhancement (LGE) was visually determined by two experienced observers (GPM/AS), and classified as 'ischaemic' or non-ischaemic' distribution, and was quantified using  $>5SD$  above the mean signal intensity of normal myocardium(23). Extracellular volume (ECV) was calculated using Hct measured on the same day. We have previously shown excellent reproducibility of ECV calculation using dual-bolus contrast injection(24). Extracellular myocardial volume index ( $ECV \times$  myocardial volume index) and myocyte volume index ( $[1 - ECV] \times$  myocardial volume index) were calculated(25). Quantitative perfusion analysis was performed using Q-mass version-7.1(4). Diogenes Feature Tracking software (TomTec Imaging Systems, Munich, Germany) was used for strain analysis(26). Pulse wave velocity (PWV) was calculated using Jim (Version 6, Xinapse systems, UK). VAI was also calculated using CMR-derived stroke volume (LVEDV-LVESV).

### Plasma Biomarkers

Blood samples were collected in EDTA tubes and centrifuged within 4 hours at 2000g for 20 minutes. Plasma was then drawn off and stored at  $-80^{\circ}C$ . Biomarker analysis was performed in a batch with a Luminex® bead-based multiplex assay(27), using antibodies from R&D Systems (Minneapolis, MN, USA). Colour-coded beads were pre-coated with a capture antibody for MMP-2, 3, 7, 8, 9, 12, TIMP-1 and 4, Syndecan-1 and 4, and added to the wells containing the sample. R-Phycoerythrin (RPE) secondary antibodies were then incubated with the samples.

After washing, the beads were read on a Luminex Bio-Plex 3D Reader (Bio-Rad, Hercules, CA, USA) (see Supplemental document). NT-proBNP was analysed using our in-house non-competitive assay that employs the quantitative sandwich enzyme immunoassay technique.

#### *Follow-up and primary endpoint*

Patients were followed up at 6-monthly intervals until a primary endpoint or end of study was reached. A primary endpoint was a composite of typical AS symptoms necessitating referral for AVR, cardiovascular death or major adverse cardiovascular events (hospitalisation with heart failure, chest pain, syncope or arrhythmia).

#### *Statistical analysis*

Baseline data was collected using electronic case-record forms, and blinded imaging data was sent to the Robertson Centre for Biostatistics, University of Glasgow, for unblinding and statistical analysis. Normally distributed data are expressed as mean±standard deviation. Non-parametric data are expressed as median[interquartile range]. Continuous variables were compared between male and female patients using independent t-tests or Mann-Whitney tests. The Chi-squared test or Fisher's exact test were used for categorical variables. Linear regression analysis was performed to look at correlations with LVMI and LV mass/volume. Univariate and multivariate associates of the primary outcome were determined using Cox proportional hazards regression and stepwise selection. Variables for the stepwise models were selected based on statistical significance ( $p < 0.05$ ) and clinical relevance (based on previously determined associations), avoiding co-linear variables.

## **Results**

### *Demographic and echocardiographic data*

174 subjects (133 male, 41 female) were recruited (table-1). Male patients were slightly older, with larger BSA. There was no difference in resting haemodynamics, incidence of most co-morbidities and common cardiovascular medication use. Men had slightly higher AVA but not when indexed to body surface area (AVAI) and had similar pressure gradients. . The septal  $E/e'$  was higher in females, as was the longitudinal peak early diastolic strain rate (PEDSR) (Speckle Tracking unanalysable in 52 patients: 41 male, 11 female). Moderate aortic regurgitation was present in five patients and none had more than mild mitral regurgitation. The demographic and remodelling data in the severe AS sub-group were similar (Supplemental Table 1).

#### *CMR data*

Male subjects had significantly higher indexed LV volumes and mass, more concentric remodelling (higher mass/volume ratio), and a lower systolic (LVEF, longitudinal and circumferential peak systolic strain) and diastolic (longitudinal and circumferential PEDSR) function than females (table-2, figure-1). Rest and stress MBF were significantly lower in males, with no difference in MPR, whilst PWV was significantly higher. The prevalence of LGE tended to be higher in male patients and extent of LGE was higher. There were 51 men and 11 women with non-infarct pattern LGE. There was no difference in native T1 but ECV was marginally higher in females but total extracellular myocardial volume and indexed extracellular myocardial volume were higher in males.

#### *Plasma Markers*

There was no significant difference in NT-proBNP levels between the sexes. Syndecan-4 and MMP-3 levels were higher in males. Whilst MMP-3 correlated with several CMR markers,

after adjusting for sex, these did not reach statistical significance. Syndecan-4 however, was associated with increased ventricular volumes (LVEDV, LVESV and RVEDV).

#### *Associations with LVMI*

**Table 4** shows univariate and multivariate associations of LVMI. Male sex was significantly associated with LVMI for the overall population and remained on multivariate analysis ( $\beta=12.10$  (7.55-16.64),  $p<0.001$ ). AV Vmax and MPG were associated with LVMI for both sexes, AVA or AVAI were not (figure-2). Whilst longitudinal strain parameters were associated with LVMI in both sexes, circumferential parameters and ejection fraction were only significant in males. NT-proBNP, left atrial volume index and markers of focal and diffuse fibrosis were associated with LVMI in male patients only. Serum biomarkers were not associated with LVMI. The following variables were entered into a stepwise multivariate model: age, VAI(CMR), AV Vmax, PWV, diabetes and BMI. AV Vmax was independently associated with LVMI in both sexes, whilst VAI and BMI was also associated in males. Univariate and multivariate associations of LV mass/volume are shown in Supplemental Table 2.

#### *Associations with primary outcome*

During median follow-up of 374 (IQR 351-498) days, 18 (43.9%) females developed symptoms (1 of whom died shortly after symptom onset), compared to 29 (21.8%) endpoints in males (28 symptom onset and 1 sudden death) (RR 0.50 (CI 0.31, 0.80),  $p=0.004$ ). There were no other MACE endpoints. Measures of AS severity were associated with the primary outcome in both sexes, whereas NT-proBNP, MMP3 and mass/volume were only associated in males (table-5). The following variables were entered into the stepwise multivariate model:  $\log_{10}$ (NT-proBNP),  $\log_{10}$ (MMP3), AV Vmax, VAI(CMR), LV mass/Volume, MPR, ECV and %LGE. On excluding ECV from the model,  $\log_{10}$ (NTpro-BNP) was significant for male patients instead.

## Discussion

This is the first study to show that significant sex differences in CMR-detected fibrosis are associated with plasma biomarkers of LV remodelling and fibrosis, in asymptomatic patients with AS. Male patients demonstrated more concentric remodelling, cardiac dysfunction and fibrosis than females, with biomarkers associated with remodelling/fibrosis being significantly higher. Despite this, there was a higher incidence of symptom onset in females. This uncoupling of LV remodelling and symptoms between genders, that has not been recognized previously, is likely to be important in clinical management and merits further attention.

### *Remodelling*

Our finding of more concentric LV remodelling (higher mass/volume) in males is contrary to previous TTE studies showing higher relative wall thickness in females (10,28). However, TTE measurements are based on a single basal slice, usually using M-mode, which has many assumptions about the shape and symmetry of the LV. CMR overcomes many of these limitations and is now regarded as the gold standard for quantitative LV assessment (29,30). Two CMR studies have also shown higher LVMI(12,13) and LV mass/volume (12) in male AS patients and Dweck *et al* showed that male sex was associated with LVMI (31).

Contrary to previous CMR studies (12,13), we saw a strong trend ( $p=0.06$ ) towards less LGE in females. The likely reason for this apparent discrepancy is that in both previous studies, females had more severe AS and were also older in Dobson *et al*'s study. Our observation is unlikely to be spurious since females also demonstrated better function and lower levels of biomarkers associated with fibrosis. Previous histological studies have also confirmed that females have less myocardial fibrosis and lower collagen volume at the time of AVR (11).

Interestingly, ECV, which is widely regarded as a measure of diffuse interstitial fibrosis was *higher* in females than males. There are 2 likely explanations for this apparent discrepant finding. Firstly, ECV is more than just a measure of diffuse interstitial fibrosis, as it measures all the extracellular space, including the normal matrix supporting myocytes as well as intramyocardial blood vessels, and given that hematocrit tends to be lower in females, this may contribute to the higher ECV. The healthy ECV is ~25%(32), whilst interstitial fibrosis is often very low (~6.5%)(33), so in early disease ECV vastly overestimates diffuse fibrosis. Secondly, the normal range in healthy females is typically higher than males (32), so this may just represent normal values. Future studies assessing ECV should adjust for gender in their population. Consistent with females having less interstitial fibrosis was the finding of reduced total extracellular volume index.

### *Biomarkers*

Syndecan-4, a cell surface proteoglycan that promotes collagen cross-linking, was associated with increased volumes, and may play an important role in LV remodelling. Increased levels of MMP3, which is a collagenase that breaks down collagen and basement membrane components, implies increased extracellular matrix turnover and remodelling, leading to collagen accumulation and fibrosis. This is the first study to report that MMP3 has sex-dependent expression differences in asymptomatic AS. Lower MMP3 in females has been found in other conditions including bacterial sepsis, stroke, and myocardial infarction (MI) (34,35) and it predicted LV dysfunction, remodelling and mortality after MI (36). Female sex steroids reduced collagen deposition 3 fold more than testosterone in human aortic smooth muscle cells, and testosterone increased gene and protein expression of MMP3 relative to both control and female sex steroids (37). In a mouse model of pressure overload, wild-type male mice developed

eccentric hypertrophy and more pronounced cardiac fibrosis, a difference that was abolished in oestrogen receptor-beta knockout mice (38). Given that MMP3 independently predicts the primary outcome in men only, and estradiol/progesterone is associated with reduced MMP3 expression, circulating MMP3 may be central to understanding the sex differences in phenotype in AS.

Collectively these data suggest that for a given degree of AS, females adapt with less concentric remodelling and less focal myocardial fibrosis, but still have a greater incidence of spontaneous symptom onset. There are several possible explanations for this seemingly counter-intuitive finding. Our main outcome measure was symptom onset, as we wanted to identify 'pre-symptomatic' patients who may benefit from prophylactic AVR, which is quite distinct from previous studies that have correlated fibrosis and remodelling with adverse prognosis, mainly mortality, including post-AVR. Females were likely to have higher wall stress, due to less adaptive concentric remodelling for a given pressure gradient (Law of Laplace), which is supported by higher resting myocardial blood flow and numerically higher NT-proBNP levels, which may lead to earlier symptoms. And although females had less focal fibrosis, they demonstrated higher LV filling pressure (higher septal  $E/e'$  associated with a similar degree of atrial remodelling) that may limit the ability to further compensate with increasing AS severity. Another possibility is that females, particularly the elderly, tend to be less physically active (39) and there may be subjective differences in the interpretation and acknowledgement of symptoms. If symptom onset leads to earlier intervention, in combination with less irreversible fibrosis(40,41), this may also explain the better post-operative long-term survival in some female subgroups(42-44).

### *Limitations*

The number of female participants, and hence the number of endpoints reached, were relatively low, leading to limitations in statistical interpretation, particularly in multivariate analysis, and the findings should be confirmed in additional studies. Clinical outcome was, as expected, driven by symptom development and not hard clinical endpoints. However, symptoms heralds a rapid decline in prognosis and is an indication for AVR, so we feel this is a valid outcome measure. Although all fibrosis parameters tended to be higher in males than females, the difference for non-infarct LGE was not statistically significant. We measured circulating biomarkers associated with myocardial fibrosis but we cannot be certain that there is no contribution from other tissues.

### **Conclusions**

Asymptomatic male patients with moderate to severe AS demonstrate more concentric LV remodelling, a trend to more myocardial fibrosis (and increased plasma markers of fibrosis) and cardiac dysfunction than females. However, there is dissociation between LV remodelling/fibrosis and symptom onset, which was more common in females, which requires further investigation.

### **Competency in medical knowledge**

This work enhances our understanding of the gender differences in remodelling and symptom onset in AS, and their associations with biomarkers.

### **Translational outlook**

This study highlights the need for further studies to establish the reasons for differential remodelling and symptom onset between sexes, and perhaps explore if sex-specific definitions of AS severity may have a role in the future.

## References

1. Nkomo V, Gardin J, Skelton T, Gottdiener J, Scott C, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet* 2006;368:1005-1011.
2. Carabello BA. The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. *J Heart Valve Dis* 1995;4 Suppl 2:S132-8; discussion S138-9.
3. Rajappan K, Rimoldi OE, Dutka DP et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. *Circulation* 2002;105:470-6.
4. Steadman CD, Jerosch-Herold M, Grundy B et al. Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. *J Am Coll Cardiol Img* 2012;5:182-9.
5. Flett AS, Sado DM, Quarta G et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. *Eur Heart J Cardiovasc Imaging* 2012;13:819-26.
6. Hein S, Arnon E, Kostin S et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation* 2003;107:984-91.
7. Hess OM, Ritter M, Schneider J, Grimm J, Turina M, Krayenbuehl HP. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. *Circulation* 1984;69:855-65.

8. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? *Eur Heart J* 2005;26:1790-6.
9. Carroll JD, Carroll EP, Feldman T et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. *Circulation* 1992;86:1099-107.
10. Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients > 60 years of age with aortic stenosis. *Am J Cardiol* 1994;74:794-8.
11. Villari B, Campbell SE, Schneider J, Vassalli G, Chiariello M, Hess OM. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. *Eur Heart J* 1995;16:1410-9.
12. Lee JM, Park SJ, Lee SP et al. Gender Difference in Ventricular Response to Aortic Stenosis: Insight from Cardiovascular Magnetic Resonance. *PLoS One* 2015;10:e0121684.
13. Dobson LE, Fairbairn TA, Musa TA et al. Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study. *Am Heart J* 2016;175:101-11.
14. Kararigas G, Dworatzek E, Petrov G et al. Sex-dependent regulation of fibrosis and inflammation in human left ventricular remodelling under pressure overload. *Eur J Heart Fail* 2014;16:1160-7.

15. Fondard O, Detaint D, Jung B et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. *Eur Heart J* 2005;26:1333-41.
16. Collier P, Watson CJ, Voon V et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? *Eur J Heart Fail* 2011;13:1087-95.
17. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. *J Am Coll Cardiol* 2004;44:1609-18.
18. Lunde IG, Herum KM, Carlson CC, Christensen G. Syndecans in heart fibrosis. *Cell Tissue Res* 2016;365:539-52.
19. Singh A, Ford I, Greenwood JP et al. Rationale and design of the PRognostic Importance of Microvascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. *BMJ Open* 2013;3:e004348.
20. Singh A, Greenwood JP, Berry C et al. Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. *Eur Heart J* 2017;10.1093/eurheartj/ehx001.
21. Baumgartner H, Hung J, Bermejo J et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr* 2009;22:1-23.

22. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. *J Am Coll Cardiol* 2009;54:1003-11.
23. Flett AS, Hasleton J, Cook C et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. *J Am Coll Cardiol Img* 2011;4:150-6.
24. Singh A, Horsfield MA, Bekele S, Khan JN, Greiser A, McCann GP. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. *Eur Heart J Cardiovasc Imaging* 2015;16:763-70.
25. Chin CW, Everett RJ, Kwiecinski J et al. Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis. *JACC Cardiovasc Imaging* 2016;10.1016/j.jcmg.2016.10.007.
26. Khan JN, Singh A, Nazir SA, Kanagala P, Gershlick AH, McCann GP. Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction. *Eur J Radiol* 2015;84:840-8.
27. Tang H, Panemangalore R, Yarde M, Zhang L, Cvijic ME. 384-Well Multiplexed Luminex Cytokine Assays for Lead Optimization. *J Biomol Screen* 2016;21:548-55.
28. Douglas PS, Otto CM, Mickel MC, Labovitz A, Reid CL, Davis KB. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. *NHLBI Balloon Valvuloplasty Registry. Br Heart J* 1995;73:548-54.

29. Grothues F, Smith GC, Moon JC et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol* 2002;90:29-34.
30. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. *Eur Heart J* 2009;30:98-106.
31. Dweck MR, Joshi S, Murigu T et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2012;14:50.
32. Sado DM, Flett AS, Banypersad SM et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. *Heart* 2012;98:1436-41.
33. Rossi MA. Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis. *Med Sci Monit* 2001;7:820-32.
34. Collazos J, Asensi V, Martin G, Montes AH, Suarez-Zarracina T, Valle-Garay E. The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and non-infectious conditions. *Clin Exp Immunol* 2015;182:213-9.

35. Samnegard A, Hulthe J, Silveira A, Ericsson CG, Hamsten A, Eriksson P. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. *Atherosclerosis* 2009;202:550-6.
36. Kelly D, Khan S, Cockerill G et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. *Eur J Heart Fail* 2008;10:133-9.
37. Natoli AK, Medley TL, Ahimastos AA et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. *Hypertension* 2005;46:1129-34.
38. Fliegner D, Schubert C, Penkalla A et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. *Am J Physiol Regul Integr Comp Physiol* 2010;298:R1597-606.
39. Rosenfeld CS. Sex-dependent differences in voluntary physical activity. *J Neurosci Res* 2017;95:279-290.
40. Weidemann F, Herrmann S, Stork S et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. *Circulation* 2009;120:577-84.
41. Dweck MR, Joshi S, Murigu T et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. *J Am Coll Cardiol* 2011;58:1271-9.
42. Kulik A, Lam BK, Rubens FD et al. Gender differences in the long-term outcomes after valve replacement surgery. *Heart* 2009;95:318-26.
43. Fuchs C, Mascherbauer J, Rosenhek R et al. Gender differences in clinical presentation and surgical outcome of aortic stenosis. *Heart* 2010;96:539-45.

44. Conrotto F, D'Ascenzo F, Presbitero P et al. Effect of gender after transcatheter aortic valve implantation: a meta-analysis. *Ann Thorac Surg* 2015;99:809-16.

## Figure Legends

### **Figure-1. An example of a male (top panel) and female (bottom panel) patient with similar degree of aortic stenosis.**

The figure shows the end-diastolic frame of a short-axis cine (a,e), and-systolic still of a 3-chamber cine (b,f), native T1 map (c,g) and late-gadolinium enhancement image (d,h) with insertion point non-infarct pattern LGE in the male patient (arrows). (Male: AVAI=0.41cm<sup>2</sup>/m<sup>2</sup>, LVEDVI=122 ml/m<sup>2</sup>, LVMI=110g/m<sup>2</sup>, mass/vol=0.90; Female: AVAI=0.36cm<sup>2</sup>/m<sup>2</sup>, LVEDVI=71 ml/m<sup>2</sup>, LVMI=33g/m<sup>2</sup>, mass/vol=0.0.47)

### **Figure-2. Relationship between left ventricular mass index and markers of AS severity in male and female patients.**

Positive correlation of LVMI with AV Vmax and MPG, and no correlation with AVAI.

**Table 1. Demographic and echocardiographic data**

	All (n=174)	Male (n=133)	Female (n=41)	p-value
<b>Demographic data</b>				
Age (years)	66.2 ± 13.34	67.3 ± 12.64	62.9 ± 15.08	0.066
BMI (kg/m <sup>2</sup> )	28.0 ± 4.15	28.0 ± 4.04	27.9 ± 4.53	0.826
BSA (m <sup>2</sup> )	2.0 ± 0.21	2.0 ± 0.18	1.8 ± 0.17	<0.001*
HR (bpm)	70.3 ± 11.43	70.0 ± 11.11	71.2 ± 12.50	0.561
SBP (mmHg)	146.9 ± 21.09	148.2 ± 20.14	142.7 ± 23.70	0.146
DBP (mmHg)	77.2 ± 10.65	78.0 ± 10.40	74.3 ± 11.06	0.049*
Diabetes (n (%))	25 (14.4)	21 (15.8)	4 (9.8)	0.336
Hypertension (n (%))	93 (53.4)	70 (52.6)	23 (56.1)	0.697
Hyperlipidaemia (n (%))	92 (52.9)	78 (58.6)	14 (34.1)	0.015*
ACE-I/ARB (n (%))	77 (44.3)	58 (43.6)	19 (46.3)	0.758
Beta-blocker (n (%))	54 (31.0)	39 (29.3)	15 (36.6)	0.380
Statin	105 (60.3)	82 (61.7)	23 (56.1)	0.525
<b>Echocardiography data</b>				
AV Vmax (m/s)	3.86 ± 0.56	3.83 ± 0.54	3.97 ± 0.61	0.154
MPG (mmHg)	35.4 ± 12.49	34.5 ± 12.05	38.0 ± 13.66	0.121
AVA <sub>I</sub> (cm <sup>2</sup> /m <sup>2</sup> )	0.57 ± 0.14	0.58 ± 0.14	0.55 ± 0.15	0.206
AVA (cm <sup>2</sup> )	1.12 ± 0.31	1.16 ± 0.30	0.96 ± 0.28	<0.001*
Severe AS (n(%))	123 (70.7)	93 (69.9)	30 (73.2)	0.845
E/A	0.88 ± 0.29	0.86 ± 0.26	0.96 ± 0.35	0.079
Septal E/e'	12.28 ± 4.86	11.71 ± 4.15	14.20 ± 6.43	0.029*
Lateral E/e'	9.88 ± 3.72	9.56 ± 3.43	10.94 ± 4.46	0.080
VAI (mmHg/ml/m <sup>2</sup> )	3.96 ± 1.06	3.99 ± 1.08	3.86 ± 1.00	0.508
Longitudinal PSS (%)	-18.18 ± 2.76	-17.97 ± 2.79	-18.82 ± 2.58	0.140
Longitudinal PEDSR (1/s)	0.79 ± 0.21	0.76 ± 0.19	0.86 ± 0.25	0.024*

Abbreviations: BMI=body mass index, BSA=body surface area, HR=heart rate, SBP/DBP=systolic/diastolic blood pressure, ACE-I=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, AV Vmax=peak aortic jet velocity, MPG=mean pressure gradient, AVAI=aortic valve area indexed to BSA, AS=aortic stenosis, DPT=diastolic perfusion time, VAI=valvulo-arterial impedance, PSS=peak systolic strain, PEDSR=peak early diastolic strain rate

**Table 2. CMR data for male and female patients**

	Male (n=133)	Female (n=41)	p-value
<b>LVEDVI (ml/m<sup>2</sup>)</b>	90.00 ± 18.67	79.74 ± 14.50	0.002*
<b>LVESVI (ml/m<sup>2</sup>)</b>	39.97 ± 10.70	32.80 ± 8.49	<0.001*
<b>LVSVI (ml/m<sup>2</sup>)</b>	50.04 ± 9.71	46.92 ± 7.48	0.061
<b>LVEF (%)</b>	55.9 ± 4.84	59.2 ± 4.49	<0.001*
<b>LVMI (g/m<sup>2</sup>)</b>	60.54 ± 13.70	48.45 ± 9.74	<0.001*
<b>LV mass/volume (g/ml)</b>	0.68 ± 0.11	0.61 ± 0.11	0.001*
<b>Myocyte volume index (ml/m<sup>2</sup>)</b>	42.28 [36.9, 48.2]	32.77 [30.6, 39.1]	<0.001*
<b>Extracellular volume index (ml/m<sup>2</sup>)</b>	13.27 [11.5, 17.0]	11.53 [10.5, 13.5]	0.017*
<b>LAVI (ml/m<sup>2</sup>)</b>	54.81 ± 14.43	55.46 ± 15.98	0.807
<b>RVEDVI (ml/m<sup>2</sup>)</b>	91.26 ± 14.48	78.39 ± 13.07	<0.001*
<b>VAI (mmHg/ml/m<sup>2</sup>)</b>	3.77 ± 0.81	3.95 ± 0.86	0.231
<b>PWV (m/s)</b>	8.76 ± 3.73	7.25 ± 2.71	0.005*
<b>Stress MBF (ml/min/g)</b>	2.09 ± 0.66	2.39 ± 0.80	0.020*
<b>Rest MBF (ml/min/g)</b>	0.93 ± 0.21	1.14 ± 0.36	0.002*
<b>MPR</b>	2.29 ± 0.70	2.18 ± 0.70	0.380
<b>LGE present (n,%)</b>	68 (51.1)	14 (34.1)	0.057
<b>Non-infarct LGE (n,%)</b>	51 (38.3)	11 (26.8)	0.178
<b>LGE (g)</b>	3.39 [10.6, 6.9]	0.95 [0.44, 2.7]	<0.001*
<b>% LGE (%)</b>	3.70 [1.03, 7.00]	1.60 [0.65, 4.30]	0.007*
<b>Native T1 (ms)</b>	1137.2 ± 71.06	1115.3 ± 62.73	0.139
<b>ECV (%)</b>	24.57 ± 2.54	25.64 ± 1.85	0.044*
<b>Longitudinal PSS (%)</b>	-17.85 ± 2.80	-20.52 ± 2.81	<0.001*
<b>Longitudinal PEDSR (1/s)</b>	1.04 ± 0.27	1.25 ± 0.26	0.030*
<b>Circumferential PSS (%)</b>	-27.64 ± 4.83	-29.56 ± 3.74	0.021*
<b>Circumferential PEDSR (1/s)</b>	1.60 ± 0.39	1.91 ± 0.36	<0.001*

Abbreviations: As in Table-1 and LVEDVI=left ventricular end-diastolic volume indexed to BSA, LVESVI=left ventricular end systolic volume indexed to BSA, LVSVI=left ventricular stroke volume indexed to BSA, LVEF=left ventricular ejection fraction, LVMI=left ventricular mass indexed to BSA, LAVI=left atrial volume indexed to BSA, RVEDVI=right ventricular end diastolic volume indexed to BSA, PWV=pulse wave velocity, MPR=myocardial perfusion reserve, MBF=myocardial blood flow, LGE=late gadolinium enhancement, ECV=extracellular volume

**Table 3. Plasma biomarker data for male and female patients**

	<b>Male (n=33)</b>	<b>Female (n=41)</b>	<b>p-value</b>
<b>MMP 2 (ng/mL)</b>	806 [503, 3615]	731 [469, 2230]	0.471
<b>MMP 3 (ng/mL)</b>	26.1 [15.3, 114.8]	17.6 [9.3, 46.8]	0.041*
<b>MMP 7 (pg/mL)</b>	823 [396, 1379]	735 [415, 1701]	0.638
<b>MMP 8 (ng/mL)</b>	2.28 [0.02, 5.66]	1.49 [0.02, 5.34]	0.659
<b>MMP 9 (ng/mL)</b>	93.9 [41.8, 214]	141 [59.6, 269]	0.429
<b>MMP 12 (pg/mL)</b>	67.8 [4.15, 117]	38.4 [4.15, 107]	0.842
<b>TIMP 1 (ng/mL)</b>	392 [269, 531]	344 [205, 519]	0.208
<b>TIMP 4 (ng/mL)</b>	3.8 [0.75, 379.7]	1.9 [0.51, 379.7]	0.116
<b>Syndecan 1 (pg/mL)</b>	185 [102, 319]	170 [73.1, 287]	0.464
<b>Syndecan 4 (pg/mL)</b>	213 [84.8, 449]	141 [1.07, 260]	0.043*
<b>NT-proBNP (pg/mL)</b>	53.8 [17.4, 144]	73.4 [22.7, 243]	0.165

Results expressed as median [IQR]. MMP=Matrix Metalloproteinase, TIMP=Tissue Inhibitor of Matrix Metalloproteinase, NT-proBNP=N terminal brain natriuretic peptide

**Table 4. Univariate and multivariate associations with LVMI in male and female patients**

Variable	Male		Female	
	Estimate (95% CI)	p-value	Estimate (95% CI)	p-value
Age	-0.18 (-0.37, 0.00)	0.053	-0.21 (-0.40, -0.01)	<b>0.042</b>
Log(NTproBNP)	1.83 (0.55, 3.10)	<b>0.005</b>	0.07 (-1.65, 1.79)	0.932
AV Vmax	10.98 (7.03, 14.93)	<b>&lt;0.001</b>	7.30 (2.72, 11.88)	<b>0.003</b>
MPG	0.48 (0.31, 0.66)	<b>&lt;0.001</b>	0.32 (0.11, 0.52)	<b>0.004</b>
AVAI	0.45 (-16.9, 17.77)	0.959	12.99(-7.62, 33.60)	0.210
Septal E/e'	-0.18 (-0.76, 0.40)	0.540	-0.65 (-1.45, 0.14)	0.106
Lateral E/e'	-0.18 (-0.94, 0.59)	0.651	-0.19 (-1.23, 0.85)	0.714
VAI (CMR)	-4.91 (-7.72, -2.10)	<b>0.001</b>	-2.55 (-6.14, 1.05)	0.160
PWV	0.05 (-0.62, 0.71)	0.892	-0.84 (-2.00, 0.33)	0.154
LAVI	0.20 (0.04, 0.36)	<b>0.017</b>	0.01 (-0.19, 0.21)	0.932
LVEF	-0.83 (-1.30, -0.36)	<b>0.001</b>	-0.44 (-1.13, 0.25)	0.204
Rest MBF	-3.10 (-14.4, 8.20)	0.588	-8.23 (-15.3, -1.15)	<b>0.024</b>
Stress MBF	-3.28 (-6.97, 0.41)	0.081	-2.74 (-6.06, 0.59)	0.103
MPR	-2.83 (-6.30, 0.64)	0.109	-0.45 (-4.42, 3.51)	0.818
LGE presence	4.98 (0.34, 9.62)	<b>0.036</b>	-1.80 (-8.35, 4.74)	0.581
LGE %	0.56 (-0.06, 1.17)	0.075	-0.44 (-1.47, 0.60)	0.398
Native T1	0.06 (0.02, 0.10)	<b>0.003</b>	0.03 (-0.03, 0.10)	0.293
ECV	1.23 (0.05, 2.42)	<b>0.042</b>	-0.67 (-2.98, 1.64)	0.556
PSS-L (CMR)	1.21 (0.38, 2.03)	<b>0.004</b>	1.18 (0.13, 2.24)	<b>0.029</b>
PEDSR-L (CMR)	-18.2 (-26.6, -9.86)	<b>&lt;0.001</b>	-14.7 (-26.0, -3.47)	<b>0.012</b>
PSS-C (CMR)	0.55 (0.06, 1.03)	<b>0.027</b>	0.05 (-0.80, 0.89)	0.913
PEDSR-C (CMR)	-10.4 (-16.2, -4.56)	<b>0.001</b>	-1.30 (-10.10, 7.48)	0.766
Log <sub>10</sub> MMP3	2.08 (-1.36, 5.53)	0.234	-1.58 (-5.26, 2.09)	0.390
Log <sub>10</sub> Syndecan4	1.53 (-0.30, 3.36)	0.100	0.46 (-1.98, 2.91)	0.702
<b>Multivariate associations:-</b>				
VAI (CMR)	-6.92 (-9.26, -4.59)	<b>&lt;0.001</b>		
AV Vmax	14.35 (10.78, 17.92)	<b>&lt;0.001</b>	7.31 (2.81, 11.81)	<b>0.003</b>
BMI	0.98 (0.51, 1.46)	<b>&lt;0.001</b>		

Abbreviations: As Table-1 and 2. Stepwise multivariate analysis after entering the following variables: age, VAI (CMR), AV Vmax, PWV, diabetes and BMI.

**Table 5. Univariate and multivariate associations with the primary outcome in male and female patients**

Variable	Male		Female	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age	1.04 (1.00, 1.09)	0.072	1.01 (0.97, 1.04)	0.695
Log(NTproBNP)	1.46 (1.08, 1.98)	<b>0.015</b>	1.19 (0.88, 1.61)	0.264
AV Vmax	3.78 (1.86, 7.69)	<b>&lt;0.001</b>	2.68 (1.21, 5.93)	<b>0.015</b>
MPG	1.06 (1.03, 1.09)	<b>&lt;0.001</b>	1.04 (1.01, 1.08)	<b>0.010</b>
AVAI	0.00 (0.00, 0.17)	<b>0.003</b>	0.01 (0.00, 0.59)	<b>0.027</b>
VAI (CMR)	1.41 (0.86, 2.31)	0.175	1.52 (0.88, 2.65)	0.134
LVMI	1.01 (0.98, 1.04)	0.374	1.02 (0.97, 1.07)	0.511
LV mass / Volume	105.7 (4.01, 2784)	<b>0.005</b>	2.70 (0.03, 232.4)	0.662
LVEDVI	0.99 (0.96, 1.01)	0.309	1.00 (0.97, 1.04)	0.815
LAVI	1.03 (1.00, 1.06)	0.059	1.00 (0.98, 1.03)	0.793
LVEF	1.05 (0.96, 1.15)	0.251	0.94 (0.84, 1.05)	0.276
MPR	0.65 (0.34, 1.24)	0.189	0.51 (0.24, 1.11)	0.092
Stress MBF	0.51 (0.24, 1.09)	0.083	0.84 (0.45, 1.57)	0.574
Rest MBF	0.67 (0.09, 5.20)	0.704	2.57 (0.87, 7.61)	0.087
LGE presence	1.55 (0.66, 3.62)	0.316	0.77 (0.27, 2.18)	0.617
LGE %	1.01 (0.91, 1.12)	0.863	1.00 (0.85, 1.17)	1.000
Native T1	1.00 (0.99, 1.01)	0.714	1.00 (0.99, 1.01)	0.751
ECV	1.19 (0.99, 1.44)	0.069	0.91 (0.67, 1.23)	0.536
PSS-L	1.01 (0.87, 1.17)	0.931	1.15 (0.95, 1.39)	0.147
PEDSR-L	1.58 (0.34, 7.38)	0.563	0.85 (0.12, 5.81)	0.866
PSS-C	0.91 (0.83, 1.01)	0.066	1.00 (0.87, 1.14)	0.962
PEDSR-C	1.74 (0.61, 4.97)	0.303	0.95 (0.25, 3.62)	0.935
Log <sub>10</sub> MMP3	1.84 (1.04, 3.28)	<b>0.037</b>	1.25 (0.69, 2.27)	0.459
Log <sub>10</sub> Syndecan 4	0.97 (0.71, 1.34)	0.852	1.1 (0.75, 1.61)	0.617
<b>Multivariate associations:-</b>				
AV Vmax	5.29 (2.21, 12.67)	<b>&lt;0.001</b>	3.09 (1.18, 8.06)	<b>0.022</b>
ECV	1.27 (1.03, 1.57)	<b>0.026</b>		
Log <sub>10</sub> MMP 3	3.33 (1.54, 7.21)	<b>0.002</b>		

Abbreviations: As Table-1 and 2. Stepwise multivariate analysis after entering the following variables: log(NT-proBNP), AV Vmax, VAI (CMR), LV mass/Volume, MPR, ECV and %LGE. On excluding ECV from model, log(NTpro-BNP) and AV Vmax are independently associated with the primary outcome for male patients and AV Vmax remains for females.